Collaboration combines Apellis expertise in complement, a complex biological system, with Beams proprietary base editing platform
Companies will collaborate on six research programs directed to tissues modulated by the complement system, including the eye, liver, and brain
WALTHAM, Mass. and CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Beam Therapeutics Inc. (Nasdaq: BEAM) today announced an exclusive five-year research collaboration focused on the use of Beams proprietary base editing technology to discover new treatments for complement-driven diseases. The companies will collaborate on six research programs focused on C3 and other complement targets in the eye, liver, and brain.
Beam has pioneered base editing, which holds significant promise as a best-in-class technology for precision gene editing. This collaboration builds on our deep scientific expertise in complement and, together with our growing pipeline, positions Apellis for long-term leadership in the complement field, said Cedric Francois, M.D., Ph.D., co-founder and chief executive officer, Apellis. Apellis and Beam share a vision for advancing transformative medicines for patients, which is critically important as we embark on a highly innovative effort to modulate complement and discover new treatments across a wide range of debilitating diseases.
Base editing represents a potential new class of precision genetic medicine that uses a chemical reaction designed to create precise, predictable, and efficient single base changes at targeted genomic sequences without making double-stranded breaks in the DNA. Editing key elements of the complement pathway in target organs has the potential to alter the complement cascade and durably address diseases driven by abnormal complement activity.
Apellis has established itself as a leader in complement with the advancement of compelling targeted C3 therapies, said John Evans, chief executive officer, Beam. This collaboration allows us to combine our proprietary technologies and capabilities in base editing with Apellis expertise in targeting the complement pathway to develop new medicines for diseases driven by complement biology. This also represents an important strategic initiative to explore opportunities that expand the application of base editing to address more biologically complex diseases for patients in need of new treatment options.
Story continues
Under the terms of the collaboration agreement, Beam will apply its base editing technology and conduct preclinical research on up to six base editing programs that target specific genes within the complement system in various organs, including the eye, liver, and brain. Apellis will have exclusive rights to license each of the six programs and will assume responsibility for subsequent development. Beam may elect to enter a 50-50 U.S. co-development and co-commercialization agreement with Apellis with respect to one program licensed under the collaboration.
As part of the collaboration, Beam will receive a total of $75 million in upfront and near-term milestones from Apellis $50 million upon signing and an additional $25 million payment on the one-year anniversary of the contract execution date. After exercise of the opt-in license rights for each of the up to six programs, Beam will be eligible to receive development, regulatory, and sales milestones from Apellis, as well as royalty payments on sales. The collaboration has an initial term of five years and may be extended up to two years on a per year and program-by-program basis.
About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. For more information, please visit https://www.apellis.com.
About Beam TherapeuticsBeam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beams suite of gene editing technologies is anchored by base editing, a proprietary technology that enables precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Apellis Forward-Looking Statement Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements in respect of the expected closing of the exchanges. The words anticipate, believe, continue, could, estimate, expect, intend, may, plan, potential, predict, project, should, target, will, would and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether the research collaboration will result in programs that are licensed by Apellis; whether any product candidates that arise from these programs or are otherwise developed by Apellis will advance into clinical trials or through the clinical trial process on a timely basis or at all; whether the results of clinical trials of the companys product candidates will warrant submissions for regulatory approval or regulatory approval; whether any products that receive regulatory approval will be successfully distributed and marketed; and other factors discussed in the Risk Factors section of Apellis Quarterly Report on Form 10-Q with the Securities and Exchange Commission on April 28, 2021 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Beam Forward-Looking Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, statements related to: the therapeutic applications and potential of our technology, including our ability to develop life-long, curative, precision genetic medicines for patients through base editing. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our platform technology; the potential impact of the COVID-19 pandemic; risks related to competitive products; and the other risks and uncertainties identified under the heading Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2020, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, and in any subsequent filings with the Securities and Exchange Commission. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.
Contacts:
Apellis:
Media:Lissa Pavlukmedia@apellis.com617.977.6764
Investors: Argot Partners apellis@argotpartners.com212.600.1902
Beam Therapeutics:
Media:Dan Budwick1ABdan@1abmedia.com
Investors:Chelcie ListerTHRUST Strategic Communicationschelcie@thrustsc.com
- New gene offers hope for preventive medicine against fractures [Last Updated On: September 18th, 2012] [Originally Added On: September 18th, 2012]
- Colon Cancer Gene Database May Assist Research Efforts [Last Updated On: September 30th, 2012] [Originally Added On: September 30th, 2012]
- Researchers discover gene that causes deafness [Last Updated On: September 30th, 2012] [Originally Added On: September 30th, 2012]
- Gene Study Yields New Clues to Breast Cancer [Last Updated On: September 30th, 2012] [Originally Added On: September 30th, 2012]
- Gene key to chemotherapy efficacy [Last Updated On: September 30th, 2012] [Originally Added On: September 30th, 2012]
- Gene clues offer new hope for treating breast cancer [Last Updated On: September 30th, 2012] [Originally Added On: September 30th, 2012]
- Gene that causes deafness pinpointed [Last Updated On: October 1st, 2012] [Originally Added On: October 1st, 2012]
- Gene that causes a form of deafness discovered [Last Updated On: October 1st, 2012] [Originally Added On: October 1st, 2012]
- Novel gene associated with Usher syndrome identified [Last Updated On: October 2nd, 2012] [Originally Added On: October 2nd, 2012]
- Translational Regenerative Medicine: Market Prospects 2012-2022 [Last Updated On: October 2nd, 2012] [Originally Added On: October 2nd, 2012]
- Two-day test can spot gene diseases in newborns [Last Updated On: October 3rd, 2012] [Originally Added On: October 3rd, 2012]
- Fast Gene Screen May Help Sick Babies [Last Updated On: October 3rd, 2012] [Originally Added On: October 3rd, 2012]
- Gene therapies need new development models [Last Updated On: October 3rd, 2012] [Originally Added On: October 3rd, 2012]
- Rapid gene machines used to find cause of newborn illnesses [Last Updated On: October 3rd, 2012] [Originally Added On: October 3rd, 2012]
- Gene behind many spontaneous breast cancers identified [Last Updated On: October 3rd, 2012] [Originally Added On: October 3rd, 2012]
- Gene responsible for many spontaneous breast cancers identified [Last Updated On: October 3rd, 2012] [Originally Added On: October 3rd, 2012]
- Two-day test can spot gene diseases in newborns - Wed, 03 Oct 2012 PST [Last Updated On: October 3rd, 2012] [Originally Added On: October 3rd, 2012]
- Researchers Discover Gene Defect Linked to Deafness [Last Updated On: October 3rd, 2012] [Originally Added On: October 3rd, 2012]
- Gene diseases in newborns unveiled quicker [Last Updated On: October 4th, 2012] [Originally Added On: October 4th, 2012]
- Quicker gene test may help babies - Thu, 04 Oct 2012 PST [Last Updated On: October 4th, 2012] [Originally Added On: October 4th, 2012]
- Rapid gene-mapping test may diagnose disease in newborns [Last Updated On: October 5th, 2012] [Originally Added On: October 5th, 2012]
- 2-day test can spot gene diseases in newborns [Last Updated On: October 5th, 2012] [Originally Added On: October 5th, 2012]
- Gene diseases in newborns spotted with 2-day test [Last Updated On: October 5th, 2012] [Originally Added On: October 5th, 2012]
- Rare Gene Deletion Tied To Psychiatric Disease And Obesity [Last Updated On: October 10th, 2012] [Originally Added On: October 10th, 2012]
- Mount Sinai researchers discover gene signature that predicts prostate cancer survival [Last Updated On: October 10th, 2012] [Originally Added On: October 10th, 2012]
- Test Spots Newborn Gene Disease [Last Updated On: October 10th, 2012] [Originally Added On: October 10th, 2012]
- Gene signature predicts prostate cancer survival [Last Updated On: October 11th, 2012] [Originally Added On: October 11th, 2012]
- Researchers Discover Gene Signature that Predicts Prostate Cancer Survival [Last Updated On: October 11th, 2012] [Originally Added On: October 11th, 2012]
- Bioethics Panel Urges More Gene Privacy Protection [Last Updated On: October 11th, 2012] [Originally Added On: October 11th, 2012]
- High Levels of Blood-Based Protein Specific to Mesothelioma [Last Updated On: October 11th, 2012] [Originally Added On: October 11th, 2012]
- Gene clues to help tackle skin disease [Last Updated On: October 15th, 2012] [Originally Added On: October 15th, 2012]
- Additive effect of small gene variations can increase risk of autism spectrum disorders [Last Updated On: October 15th, 2012] [Originally Added On: October 15th, 2012]
- 2-gene test predicts which patients with heart failure respond best to beta-blocker drug [Last Updated On: October 16th, 2012] [Originally Added On: October 16th, 2012]
- Two-gene test predicts which patients with heart failure respond best to beta-blocker drug [Last Updated On: October 16th, 2012] [Originally Added On: October 16th, 2012]
- Gene Linked to Kidney Failure [Last Updated On: October 17th, 2012] [Originally Added On: October 17th, 2012]
- Nanoparticles seen as gene therapy advance [Last Updated On: October 17th, 2012] [Originally Added On: October 17th, 2012]
- Stem Cell Therapy for Sickle Cell Anemia - Video [Last Updated On: October 31st, 2012] [Originally Added On: October 31st, 2012]
- Sickle Cell Anemia: Stem Cell Gene Therapy - Donald Kohn - Video [Last Updated On: October 31st, 2012] [Originally Added On: October 31st, 2012]
- Finding A Cure For Cancer with Dr. Aaron Rapoport - Video [Last Updated On: October 31st, 2012] [Originally Added On: October 31st, 2012]
- First gene therapy to go on sale in Europe in 2013: company [Last Updated On: November 7th, 2012] [Originally Added On: November 7th, 2012]
- Nanomedicine: Infectious Diseases, Immunotherapy, Diagnostics, Antifibrotics, Toxicology And Gene Me - Video [Last Updated On: November 14th, 2012] [Originally Added On: November 14th, 2012]
- Stress gene linked to heart attack – Study [Last Updated On: December 20th, 2013] [Originally Added On: December 20th, 2013]
- Why not gift yourself with gene test this Christmas? [Last Updated On: December 20th, 2013] [Originally Added On: December 20th, 2013]
- "Stress gene" may raise heart attack risk in healthy people [Last Updated On: December 20th, 2013] [Originally Added On: December 20th, 2013]
- 'Stress Gene' Ups Heart Attack, Death Risk [Last Updated On: December 20th, 2013] [Originally Added On: December 20th, 2013]
- Common disorders: It's not the genes themselves, but how they are controlled [Last Updated On: December 20th, 2013] [Originally Added On: December 20th, 2013]
- What is a gene? - Genetics Home Reference [Last Updated On: December 20th, 2013] [Originally Added On: December 20th, 2013]
- Gene Medicine | Business Outline | About Us | TAKARA BIO INC. [Last Updated On: December 20th, 2013] [Originally Added On: December 20th, 2013]
- Gene Therapy Clinical Trials Worldwide [Last Updated On: December 20th, 2013] [Originally Added On: December 20th, 2013]
- Genentech - Official Site [Last Updated On: December 21st, 2013] [Originally Added On: December 21st, 2013]
- Gene Therapy - American Medical Association [Last Updated On: December 23rd, 2013] [Originally Added On: December 23rd, 2013]
- Researchers identify gene that influences the ability to remember faces [Last Updated On: December 24th, 2013] [Originally Added On: December 24th, 2013]
- Gene That Influences Bonding Also Found To Impact Facial Recognition [Last Updated On: December 24th, 2013] [Originally Added On: December 24th, 2013]
- Gene Therapy Method Targets Tumor Blood Vessels [Last Updated On: December 24th, 2013] [Originally Added On: December 24th, 2013]
- Latin Americans inherited diabetes gene risk from Neanderthals [Last Updated On: December 26th, 2013] [Originally Added On: December 26th, 2013]
- Gene that influences the ability to remember faces identified [Last Updated On: December 30th, 2013] [Originally Added On: December 30th, 2013]
- Study supports a causal role in narcolepsy for a common genetic variant [Last Updated On: January 2nd, 2014] [Originally Added On: January 2nd, 2014]
- Increasing Investments in Molecular Biology Research Drives the Market for DNA Gene Chips, According to a New Trend ... [Last Updated On: January 2nd, 2014] [Originally Added On: January 2nd, 2014]
- Loss of Function of a Single Gene Linked to Diabetes in Mice [Last Updated On: January 3rd, 2014] [Originally Added On: January 3rd, 2014]
- Gene Medicine and Health [Last Updated On: January 3rd, 2014] [Originally Added On: January 3rd, 2014]
- Gene Therapy - Nature [Last Updated On: January 5th, 2014] [Originally Added On: January 5th, 2014]
- KidsHealth for Parents - Gene Therapy and Children [Last Updated On: January 5th, 2014] [Originally Added On: January 5th, 2014]
- Gene Patent Case Fuels U.S. Court Test of Stem Cell Right [Last Updated On: January 6th, 2014] [Originally Added On: January 6th, 2014]
- Gene Mutation Increases Certain Health Risks For Blacks, Study Finds [Last Updated On: January 6th, 2014] [Originally Added On: January 6th, 2014]
- Single faulty gene causes major type 2 diabetes symptom in mice [Last Updated On: January 6th, 2014] [Originally Added On: January 6th, 2014]
- No 'brakes' -- Study finds mechanism for increased activity of oncogene in certain cancers [Last Updated On: January 6th, 2014] [Originally Added On: January 6th, 2014]
- AML score that combines genetic and epigenetic changes might help guide therapy [Last Updated On: January 9th, 2014] [Originally Added On: January 9th, 2014]
- Stem cell research identifies new gene targets in patients with Alzheimer's disease [Last Updated On: January 9th, 2014] [Originally Added On: January 9th, 2014]
- 14 new gene targets in Alzheimer’s identified [Last Updated On: January 10th, 2014] [Originally Added On: January 10th, 2014]
- Scientists uncover new target for brain cancer treatment [Last Updated On: January 11th, 2014] [Originally Added On: January 11th, 2014]
- Tweaking MRI to Track Creatine May Spot Heart Problems Earlier, Penn Medicine Study Suggests [Last Updated On: January 13th, 2014] [Originally Added On: January 13th, 2014]
- RSNA: Gene Variation Associated with Brain Atrophy in Mild Cognitive Impairment [Last Updated On: January 14th, 2014] [Originally Added On: January 14th, 2014]
- Keeping Stem Cells Pluripotent [Last Updated On: January 14th, 2014] [Originally Added On: January 14th, 2014]
- Gene variation associated with brain atrophy in mild cognitive impairment [Last Updated On: January 14th, 2014] [Originally Added On: January 14th, 2014]
- Genes: MedlinePlus Medical Encyclopedia - National Library of ... [Last Updated On: January 15th, 2014] [Originally Added On: January 15th, 2014]
- Gene Therapy May Restore Sight in People With Rare Blinding Disease [Last Updated On: January 16th, 2014] [Originally Added On: January 16th, 2014]
- Gene therapy treats blindness [Last Updated On: January 16th, 2014] [Originally Added On: January 16th, 2014]
- New Genetic Clue to Lupus Is Found [Last Updated On: January 17th, 2014] [Originally Added On: January 17th, 2014]
- New Gene Machine Could Mean More Accurate Diagnosis [Last Updated On: January 18th, 2014] [Originally Added On: January 18th, 2014]
- Same cell death pathway involved in three forms of blindness, study finds [Last Updated On: January 18th, 2014] [Originally Added On: January 18th, 2014]